The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can ...

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.

David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...

Eli Lilly (LLY, Financial) is set to pivot its focus beyond obesity after a monumental windfall from its GLP-1 drugs. At its ...

Pharmaceutical company Eli Lilly (LLY) has been raking it in lately thanks to its two flagship products: Mounjaro and Zepbound. These two have ...

One participant lost 22% of her weight in nine months — substantially faster than the rate seen with approved GLP-1 drugs ...

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Eli Lilly and Company's latest 10-K report for the year ended December 31, 2024, reveals significant financial growth. The company reported a revenue of $45,042.7 million, marking a 32% increase from ...

A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

For the second consecutive year in 2024, US large-cap stocks outpaced cash ... quarter of 2024, Eli Lilly and Company ...

We recently published a list of the 12 Best Long-Term Growth Stocks to Buy Now. In this article, we are going to take a look ...